A Tumor Cell Membrane‐Coated CD40 Ligand‐Encoding Oncolytic Adenovirus Serves as a Potent Nano‐Vaccine for Ovarian Cancer Immunotherapy
Authors:
- 19 January 2026
- journal article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (13) , e03175
Abstract
Oncolytic virus‐based vaccines for advanced ovarian cancer have limitations owing to their receptor‐dependent tropism, host immune clearance, and ascites‐mediated viral neutralization. To mitigate these drawbacks, a novel nano‐vaccine platform was developed by incorporating immunostimulatory oncolytic adenoviruses within tumor cell membranes. This biomimetic system enabled sustained antigen release and tumor‐localized delivery of co‐stimulatory molecules, creating immunological hotspots through in situ viral replication and PANoptosis. The nano‐vaccine achieved selective viral tropism with a 36.3:1 tumor‐to‐liver biodistribution ratio (vs. 1.0:1 for the uncoated virus) while resisting immune/ascites interference. Oncolysis triggered immunogenic cell death, which released damage‐associated molecular patterns and drove systemic antitumor immunity. Notably, the platform enriched stem‐like TCF1 + PD‐1 + CD8 + T cell reservoirs that demonstrate enhanced effector differentiation upon PD‐1 checkpoint blockade. In models of peritoneal carcinomatosis, combination therapy with αPD‐1 induced complete tumor eradication in 50% of mice and significantly prolonged survival. Furthermore, a synergistic efficacy was observed when the nano‐vaccine was administered with cisplatin, a frontline chemotherapeutic agent. This virotherapy paradigm synergizes vaccination and immune reprogramming to dismantle immunosuppressive networks, thereby offering transformative potential against ovarian cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81802608)
- National Key Research and Development Program of China (2022YFC2704200)
- National Key Research and Development Program of China (2022YFC2704204)
This publication has 31 references indexed in Scilit:
- Natural Cell‐Inspired Nanoparticles: Preparation, Mechanisms, Applications, and Prospects for Clinical TranslationAdvanced Materials, 2025
- Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancerBiochemical Pharmacology, 2023
- Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges aheadCancer Letters, 2022
- Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse modelsCancer Letters, 2022
- Hybrid cell membrane-coated nanoparticles: A multifunctional biomimetic platform for cancer diagnosis and therapyActa Biomaterialia, 2020
- Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic CancerCancer Cell, 2020
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesMolecular Therapy-Oncolytics, 2017
- Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionImmunity, 2016
- An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene ExpressionMolecular Therapy, 2001